Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaMJ Keating, KB McCredie, H. Kantarjian et al.|Blood|1989Cited by 456
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upRichard A. Larson, H. Kantarjian, Andreas Hochhaus et al.|Leukemia|2012Cited by 440
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibAndreas Hochhaus, H. Kantarjian, Michele Baccarani et al.|Leukemia|2008Cited by 354
Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationFrancis J. Giles, Elihu H. Estey, H. Kantarjian et al.|Cancer|2001Cited by 280
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, Viktoriya Stalbovskaya, Vikas Gupta et al.|Haematologica|2015Cited by 252